Mass-action law dynamics theory and algorithm for translational and precision medicine informatics /
Provides a comprehensive overview and update of the mass-action law-based unified dose-effect biodynamics, pharmacodynamics, bioinformatics, and the combination index theorem for synergy definition (MAL-BD/PD/BI/CI). Contents advocate the fundamental MAL-PD/BI/CI/BI principle for biomedical R&D,...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Electrónico eBook |
| Idioma: | inglés |
| Publicado: |
London ; San Diego, CA :
Academic Press, an imprint of Elsevier,
[2024]
|
| Edición: | First edition. |
| Subjects: | |
| Acceso en liña: | ScienceDirect |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
MARC
| LEADER | 00000cam a22000007i 4500 | ||
|---|---|---|---|
| 001 | on1429659341 | ||
| 003 | OCoLC | ||
| 005 | 20260915095216.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 240413s2024 enk ob 001 0 eng d | ||
| 040 | |a YDX |b eng |e rda |c YDX |d OCLCO |d OCLKB |d EBLCP |d UKAHL |d OCLCQ |d YDX |d OCLCO |d OPELS |d EMU |d OCLCO |d UKKRT |d N$T |d OCLCL |d SFB |d OCLCF |d OCLCO | ||
| 019 | |a 1429613228 |a 1502836857 | ||
| 020 | |a 9780443288753 |q electronic book | ||
| 020 | |a 0443288755 |q electronic book | ||
| 020 | |z 0443288747 | ||
| 020 | |z 9780443288746 | ||
| 035 | |a (OCoLC)1429659341 |z (OCoLC)1429613228 |z (OCoLC)1502836857 | ||
| 050 | 4 | |a R858 |b .C56 2024 | |
| 060 | 4 | |a W 26.5 | |
| 082 | 0 | 4 | |a 610.285 |2 23/eng/20240712 |1 https://id.oclc.org/worldcat/ddc/E3dC7mfH8t4hXGxrBYfY4jqBm4 |
| 100 | 1 | |a Chou, Ting-Chao, |e author. |1 https://id.oclc.org/worldcat/entity/E39PBJtmtr38xcry99yY6cdvpP | |
| 245 | 1 | 0 | |a Mass-action law dynamics theory and algorithm for translational and precision medicine informatics / |c Ting-Chao Chou. |
| 250 | |a First edition. | ||
| 264 | 1 | |a London ; |a San Diego, CA : |b Academic Press, an imprint of Elsevier, |c [2024] | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 520 | |a Provides a comprehensive overview and update of the mass-action law-based unified dose-effect biodynamics, pharmacodynamics, bioinformatics, and the combination index theorem for synergy definition (MAL-BD/PD/BI/CI). Contents advocate the fundamental MAL-PD/BI/CI/BI principle for biomedical R&D, clinical trials protocol design computerized data analysis, illustrates the MAL-dynamics theory with sample analysis, and includes data entry and automated computer report print-outs. In 11 sections this book leads the reader from an introduction and overview, to trial protocols and MAL-PD/CI approach for biomedical R&D in vitro and in animals. It describes the current Landscape of International FDA Drug Evaluation, Clinical Pharmacology, and Clinical Trials Guidance. This is a valuable resource for biomedical researchers, healthcare professionals, and students seeking to harness the power of data informatics in precision medicine. | ||
| 588 | |a Description based on online resource; title from digital title page (viewed on July 12, 2024). | ||
| 505 | 0 | |a Intro -- Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics -- Copyright -- Contents -- Preface -- Abbreviations -- Acknowledgments -- Chapter I: A new alternative concept for cost-effective R& -- D: The MAL-dynamics/algorithms/digital informatics -- A. Challenges from complexity and diversity and the MAL-solutions -- B. A complementary alternative new approach to the traditional approach for biomedical R& -- D, drug evaluations, and beyond -- 1. The median-effect equation is the unified general equation of MAL dynamics of action -- 2. The combination index equation (CIE) is the unified general principle of interactions -- 3. The dose-reduction index (DRI) is an indication of reducing toxicity by drug combination synergism -- 4. The polygonogram is a diagram depicting three or more drug interactions for cocktail design -- The general unified theory is based on the mass-action law for single drugs and drug combinations -- The algorithm for drug or entity interaction simulation -- C. MAL applicability and implementations -- 1. MAL theory/algorithm-based approach vs observation/statistics-based approach -- 2. The unified MAL-PD principle integration and its general applications -- 3. MAL three unified general equations: MEE, CIE, and DRIE work together -- 4. Usefulness and limitations of MAL-PD versus PK -- Range of applicability -- Dose-dependency and end-point of measurement -- D. The PK/PD issues -- 1. Prerequisites for MAL-PD studies and clinical trials -- 2. Comparison of PD and PK: Why they are basically different principles -- References -- Chapter II: General dynamics principle for experimental design of all dose-effect analysis and computer simulation -- A. The principle and process for drug evaluation: Dose and effect analysis -- 1. FDA drug evaluation: Basic roles at OCP/OTS/CDER. | |
| 505 | 8 | |a 2. Issues of major concern -- 3. PD principle and the exact definitions of ``PDþþ and ``Synergismþþ -- B. Two different anti-HIV clinical trials: Protocol design and data analysis -- 1. Clinical trials of AZT + IFN combinations -- 2. Protocol design and results: AZT + IFN clinical trials -- 3. MAL-PD/CI-based design protocol and analysis -- C. Clinical trials of AZT+3TC based on the traditional statistical approach -- 1. Protocol design for AZT, 3-TC, and their combinations (AZT+3TC) in clinical trials -- 2. The results and conclusions for AZT + 3TC clinical trials -- D. Comparisons of two clinical trials: AZT + 3TC vs AZT + IFN -- E. Efficiency, cost-effectiveness, and integrative computerized automation -- F. Preclinical and clinical trials: Definitions of ``additive effect,þþ ``synergism,þþ and ``antagonismþþ -- References -- Chapter III: MAL-PD/CI approach for biomedical R& -- D in vitro and in animals -- A. Sample size, efficiency, and cost-effectiveness -- B. Significance of the MAL-PD approach -- 1. Reliability and accuracy of measurement -- 2. Avoid the extreme numbers and unreliable results -- 3. Selection of the end-point for measurement -- C. Illustration of drug combination in vitro using MAL-PD/CI method -- D. Illustration of drug combination in animals using MAL-PD/CI method -- E. Application of MAL-PD/CI method in organ transplantation studies -- References -- Chapter IV: Implementation of MAL-PD for Econo-Green R& -- D -- A. Availability of computer software for automated MAL-PD/CI/BI -- B. Comparisons and ranking of candidate drugs and biosimilars in vitro and in vivo using the same MAL-PD principle -- C. Standardized drug evaluations for single drugs using the median-effect principle of MAL-PD -- References -- Chapter V: Digital R&. | |
| 505 | 8 | |a D approach to international FDA drug evaluation, clinical pharmacology, and clinical trial guidance -- A. The observatory statistical PK principle plays an important role in FDA policy and priority -- B. Modernization of drug evaluation guidance and guidelines -- C. Why FDA drug evaluation is so relevant to a pharmacologist -- D. New avenues for integrated and streamlined drug evaluation -- E. The international FDA guidance and drug evaluation guidelines need an update and modernization -- F. The current uncertainty, ambiguity, and confusion in drug R& -- D and regulations -- References -- Chapter VI: The epothilone story: Experimental success and clinical failure -- A. A pharmacologist and theoretical biologist for life -- B. Epothilones: The interaction between chemists and pharmacologists -- C. Anticancer epothilone preclinical studies as examples -- D. Major MAL-PD findings of epothilones -- E. A clinical trial study of isofludelone (KOS-1803) -- F. A review of the failure of the isofludelone [KOS-1803] clinical trial -- References -- Chapter VII: MAL-PD advocacy: Public hearing, public comments and scientific recommendations -- A. Public meetings and public hearings at US FDA -- B. Public comments to FDA -- C. Presentation on MAL-PD theory and applications at CPIM, OTS, FDA -- D. The problem of undefinable vague ``modelsþþ -- E. Consolidation and definition of precision medicine, translational medicine, and digital biology -- References -- Chapter VIII: Consensus for international FDAs on definitions of ``MAL-PDþþ and ``Synergismþþ -- A. The role of drug evaluation from international FDAs on drug evaluation -- B. The International Council for Harmonization on ``PDþþ and ``synergismþþ for R& -- D -- C. Different thinking for the clinical trial protocol design and data analysis/simulation -- References. | |
| 505 | 8 | |a Chapter IX: Historical, philosophical, and mathematical analysis: Why the MAL-PD approach and the traditional approach ar ... -- A. The MAL theory-based ``top-downþþ versus the experimental observation-based ``bottom-upþþ for bio-R& -- D and clinical trials -- B. The inspiration and support from the visionary giants -- C. Nature's equilibrium ecosystem and interdisciplinary common basic principle from ancient to modern -- D. Artificial intelligence, cloud computing, computer learning, open AI, generative AI, and ChatGPT are the bottom-up pla ... -- 1. The mighty AI for speed, volume, accuracy, and Inference -- 2. Evidence of limitations of AI usefulness and risk -- E. Conversation with ChatGPT: Statements, informatics, errors, and this author's comments -- 1. The Conversations between a bio-medical scientist and ChatGPT on MAL-PD: T.C. Chou's comments and corrections -- 2. The Conversations between a librarian and ChatGPT on MAL-PD: T.C. Chou's comments and corrections -- 3. Chou's general comments on the ChatGPT answers -- F. System, pattern, combinatorial, number theory, and new frontiers for further mathematical developments: The contractio ... -- 1. Nature's mass-action law as the model -- 2. Patterns and mechanistic randomness in linear and circular input and output events of enzyme reactions -- l-Asparagine biosynthesis (Chou Ph.D. thesis 1970, Yale University) -- 3. Nature's MAL new revelations -- A mathematical approach to deducing kinetic mechanisms (see Appendix VI for more details) -- For the linear enzyme reaction sequences in the linear system -- For the circular enzyme mechanism system -- Pattern analysis of enzyme reaction system -- 4. MAL bio-model leads to the Second-Degree Pascal Triangle -- A mathematical new triangle derived from a biochemical input and output model -- Pattern and combinatorial analysis. | |
| 505 | 8 | |a G. The author rank-weighted triangle and algorithm for citation attribution in n-authored papers -- 1. Assumptions and definitions -- 2. The authorship-rank weighted triangle and algorithm -- 3. The approach of combinatory-pattern and system analysis in research -- 4. The derivation of the general attribution equation for n-authored papers -- 5. The general algorithm for computerized simulation -- 6. Discussions and recommendations for multiple-authored papers -- 7. The Broadness of applicability of a single paper -- H. The perspectives of the MAL-BP/PD/CI informatics -- References -- Chapter X: Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method -- A. Applications MAL-PD and CI in cancer-related research -- 1. Anticancer and antiviral agents -- B. Applications in antimicrobial research -- C. Applications in basic biomedical sciences (2020-23) -- D. MAL-PD theory/method of applications in different disciplines -- E. Applications in immunology and organ transplantation -- F. Philosophical propositions, AI, conceptual discussions and theoretical biology -- G. Early theoretical, physical, biophysical, biochemical, and elementary particle studies -- H. Other theories and concepts of non-MAL-PD approach, computer learning and artificial intelligence -- References -- Chapter XI: Concluding remarks -- References -- Postscript -- Summary -- Appendix I -- Appendix II -- Appendix III -- Appendix IV -- Appendix V -- Appendix VI -- Glossary and definitions -- References -- Research supports -- Research supports -- Conflict of interest -- Disclaimer/Publishers note -- Declarations -- Index. | |
| 650 | 0 | |a Medical informatics. | |
| 650 | 0 | |a Clinical trials |x Data processing. | |
| 650 | 2 | |a Medical Informatics |0 (DNLM)D008490 | |
| 650 | 6 | |a Médecine |x Informatique. |0 (CaQQLa)201-0103112 | |
| 650 | 6 | |a Études cliniques |0 (CaQQLa)201-0070699 |x Informatique. |0 (CaQQLa)201-0380011 | |
| 650 | 7 | |a Clinical trials |x Data processing |2 fast |0 (OCoLC)fst00864430 | |
| 650 | 7 | |a Medical informatics |2 fast |0 (OCoLC)fst01014175 | |
| 776 | 0 | 8 | |c Original |z 0443288747 |z 9780443288746 |w (OCoLC)1397563442 |
| 856 | 4 | 0 | |3 ScienceDirect |u https://www.sciencedirect.com/science/book/9780443288746 |